Neurotransmitter interactions in psychotropic drug action: Beyond dopamine and serotonin

Journal of Psychiatry and Neuroscience

Volumn 28, Issue 4, 2003, Pages 247-250

  Greenshaw, Andrew J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antipsychotic agents; Dopamine; Drug therapy; Magnetic resonance imaging; Mood disorders; Schizophrenia; Serotonin

Indexed keywords

CHLORPROMAZINE; DESIPRAMINE; DOPAMINE; HALOPERIDOL; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN 2A ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CATECHOLAMINE BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; MOOD DISORDER; PHARMACOLOGICAL BLOCKING; SCHIZOPHRENIA; SEROTONIN BRAIN LEVEL; SIDE EFFECT;

ANIMALS; BRAIN; DOPAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; NEUROTRANSMITTER AGENTS; PSYCHOTROPIC DRUGS; SEROTONIN;

EID: 0141678889     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Tran PV, Bymaster FP, McNamara RK, Potter WZ. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003;23(1):78-86.
2. Young SN, Leyton M. The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. Pharmacol Biochem Behav 2002;71(4):857-65.
3. Blier P, Haddjeri N, Szabo ST, Dong J. Enhancement of serotoninergic function - a sometimes insufficient cause of antidepressant action. Hum Psychopharmacol 2001;16(1):23-7.
4. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 2003;13(2):57-66.
5. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160(1):13-23.
6. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156(6):876-84.
7. Robbins TW. Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp Brain Res 2000;133(1):130-8.
8. Dalley JW, McGaughy J, O'Connell MT, Cardinal RN, Levita L, Robbins TW. Distinct changes in cortical acetylcholine and noradrenaline efflux during contingent and noncontingent performance of a visual attentional task. J Neurosci 2001;21(13):4908-14.
9. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002;71(4):533-54.
10. Rotzinger S, Vaccarino FJ. Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models. J Psychiatry Neurosci 2003;28(3):171-81.
11. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002;52(6):503-28.
12. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003;160(2):303-9.
13. Zanardi R, Artigas F, Moresco R, Colombo C, Messa C, Gobbo C, et al. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J Clin Psychopharmacol 2001;21(1):53-8.
14. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002;7(Suppl 1):S71-80.
15. Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003;160(3):577-9.
16. Breiter HC, Rosen BR. Functional magnetic resonance imaging of brain reward circuitry in the human. Ann N Y Acad Sci 1999;877:523-47.
17. Breiter HC, Aharon I, Kahneman D, Dale A, Shizgal P. Functional imaging of neural responses to expectancy and experience of monetary gains and losses. Neuron 2001;30(2):619-39.
18. Becerra L, Breiter HC, Wise R, Gonzalez RG, Borsook D. Reward circuitry activation by noxious thermal stimuli. Neuron 2001;32(5):927-46.
19. O'Doherty J, Rolls ET, Francis S, Bowtell R, McGlone F. Representation of pleasant and aversive taste in the human brain. J Neurophysiol 2001;85(3):1315-21.
20. Krasnow B, Tamm L, Greicius MD, Yang TT, Glover GH, Reiss AL, et al. Comparison of fMRI activation at 3 and 1.5 T during perceptual, cognitive, and affective processing. Neuroimage 2003;18(4):813-26.
21. Posse S, Fitzgerald D, Gao K, Habel U, Rosenberg D, Moore GJ, et al. Real-time fMRI of temporolimbic regions detects amygdala activation during single-trial self-induced sadness. Neuroimage 2003;18(3):760-8.
22. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003;160(1):64-75.
23. Keightley ML, Winocur G, Graham SJ, Mayberg HS, Hevenor SJ, Grady CL. An fMRI study investigating cognitive modulation of brain regions associated with emotional processing of visual stimuli. Neuropsychologia 2003;41(5):585-96.
24. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003;65:193-207.
25. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003;160(4):709-19.
26. Callicott JH, Weinberger DR. Brain imaging as an approach to phenotype characterization for genetic studies of schizophrenia. Methods Mol Med 2003;77:227-47.
27. Hariri AR, Weinberger DR. Imaging genomics. Br Med Bull 2003;65:259-70.